Investigating how specific genetic factors affect kidney disease progression in African populations.

ApolipoproteinL1 Genotypes and Biomarkers of Immune Activation and Tubular Injury

NIH-funded research Boston Medical Center · NIH-10950567

This study is looking at how certain genes and signs of inflammation in the body relate to kidney problems in people with chronic kidney disease in sub-Saharan Africa, to help find better ways to manage their health.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionBoston Medical Center NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-10950567 on NIH RePORTER

What this research studies

This research focuses on understanding the relationship between apolipoprotein L1 genotypes and biomarkers that indicate immune activation and kidney injury in individuals with chronic kidney disease (CKD) in sub-Saharan Africa. By analyzing blood and urine samples from participants in the Diet, CKD, and ApolipoproteinL1 study, the research aims to identify how these biomarkers correlate with kidney function decline, particularly in those with high-risk genetic profiles. The study will help clarify whether inflammation and tubular injury contribute to CKD progression, providing insights that could lead to improved patient management.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals of African descent with chronic kidney disease, particularly those with varying apolipoprotein L1 genotypes.

Not a fit: Patients who do not have chronic kidney disease or those outside of the African ancestry may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to better understanding and management of chronic kidney disease in African populations, potentially improving patient outcomes.

How similar studies have performed: Previous research has shown promising results in understanding genetic factors related to kidney disease, but this specific approach focusing on apolipoprotein L1 in African populations is relatively novel.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.